No published data
From Mr B. T. Marrett, MRPharmS
I am writing on behalf of the HIV Pharmacy Association regarding the News item “Raltegravir alternative to efavirenz for HIV patients” (PJ, 8 August 2009, p147). It reports on an editorial published in The Lancet. The editorial quoted is based on expert opinion, and suggests potential future use of raltegravir in pregnancy.
It is important to note there are no published data regarding the use of raltegravir in pregnancy. The current summary of product characteristics states it should not be used and that animal studies have shown reproductive toxicity.
Any pharmacist caring for HIV-positive patients who want to conceive or are pregnant should exercise caution and seek alternatives where possible.
In cases where raltegravir use is unavoidable, it is important that pregnant patients are closely monitored and this is recorded in the antiretroviral pregnancy registry.
HIV Pharmacy Association
Citation: The Pharmaceutical Journal URI: 10975776
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com